ENTA vs. CDXC, XNCR, KALV, EOLS, SANA, UPB, SAGE, ALT, TNGX, and KROS
Should you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include ChromaDex (CDXC), Xencor (XNCR), KalVista Pharmaceuticals (KALV), Evolus (EOLS), Sana Biotechnology (SANA), Upstream Bio (UPB), Sage Therapeutics (SAGE), Altimmune (ALT), Tango Therapeutics (TNGX), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical products" industry.
Enanta Pharmaceuticals vs. Its Competitors
Enanta Pharmaceuticals (NASDAQ:ENTA) and ChromaDex (NASDAQ:CDXC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.
95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.4% of ChromaDex shares are owned by institutional investors. 13.9% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of ChromaDex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Enanta Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, ChromaDex has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500.
ChromaDex has a net margin of 1.62% compared to Enanta Pharmaceuticals' net margin of -149.57%. ChromaDex's return on equity of 4.85% beat Enanta Pharmaceuticals' return on equity.
ChromaDex has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than ChromaDex, indicating that it is currently the more affordable of the two stocks.
Enanta Pharmaceuticals presently has a consensus price target of $18.00, suggesting a potential upside of 128.14%. ChromaDex has a consensus price target of $9.03, suggesting a potential upside of 0.00%. Given Enanta Pharmaceuticals' higher probable upside, research analysts plainly believe Enanta Pharmaceuticals is more favorable than ChromaDex.
In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than ChromaDex. MarketBeat recorded 1 mentions for Enanta Pharmaceuticals and 0 mentions for ChromaDex. Enanta Pharmaceuticals' average media sentiment score of 1.34 beat ChromaDex's score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.
Summary
ChromaDex beats Enanta Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Enanta Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enanta Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ENTA) was last updated on 7/3/2025 by MarketBeat.com Staff
